Exelixis, Inc. $EXEL Shares Purchased by Thrivent Financial for Lutherans

Posted by Francis Steltz on May 17th, 2026

Thrivent Financial for Lutherans increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1,821.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,188,105 shares of the biotechnology company’s stock after purchasing an additional 1,126,256 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Exelixis were worth $52,075,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of EXEL. Richardson Financial Services Inc. grew its stake in Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 292 shares in the last quarter. Anchor Investment Management LLC lifted its holdings in Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after buying an additional 500 shares during the last quarter. Root Financial Partners LLC purchased a new stake in Exelixis during the 3rd quarter worth about $28,000. Activest Wealth Management purchased a new stake in Exelixis during the 4th quarter worth about $32,000. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after buying an additional 773 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Performance

Exelixis stock opened at $50.13 on Friday. The company has a market capitalization of $12.60 billion, a P/E ratio of 16.65, a PEG ratio of 1.06 and a beta of 0.38. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $51.63. The stock has a 50-day simple moving average of $44.30 and a 200-day simple moving average of $43.48.

Exelixis (NASDAQ:EXEL – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.12. The firm had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.55 EPS. As a group, analysts forecast that Exelixis, Inc. will post 3.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on EXEL shares. Morgan Stanley lifted their price target on Exelixis from $49.00 to $50.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a report on Thursday, January 22nd. TD Cowen lifted their price target on Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Wells Fargo & Company lifted their price target on Exelixis from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $47.35.

Read Our Latest Report on EXEL

Insider Activity at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 67,814 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the transaction, the executive vice president owned 381,908 shares in the company, valued at approximately $16,620,636.16. The trade was a 15.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director George Poste sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $45.71, for a total value of $2,742,600.00. Following the transaction, the director owned 118,832 shares in the company, valued at $5,431,810.72. The trade was a 33.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 382,811 shares of company stock worth $17,014,813 in the last three months. 2.60% of the stock is currently owned by corporate insiders.

Exelixis Profile

(Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.